Johnson Research & Development (United States)

Recent papers from Johnson Research & Development (United States)

1. Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experienceHematology · 2026
2. Development and optimization of a mobile affinity selection chromatography method for analysis of therapeutic monoclonal antibody aggregates in the presence of human serum albuminJournal of Chromatography B · 2026
3. Real-world Clinical Effectiveness of Guselkumab and Its Impact on Quality of Life and Sexual Quality of Life in Patients with Genital Psoriasis: Results from the CASSIOPEE StudyBritish Journal of Dermatology · 2026
4. Quantum Pharmacophore-Based Virtual Screening Enables Prospective Discovery of Chemotype-Diverse Dengue NS5 InhibitorsJournal of Chemical Information and Modeling · 2026
5. Prioritizing Discovery and Advancements in Arrhythmia TherapiesJACC. Clinical electrophysiology · 2026
6. Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trialsSkin Health and Disease · 2026
7. US Retina Specialists’ Preferences for Geographic Atrophy TreatmentClinical ophthalmology · 2026
8. siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresJournal of Hepatology · 2026
9. Risk prediction of pneumocystis jirovecii pneumonia in kidney transplant recipients using a clinical nomogramFrontiers in Cellular and Infection Microbiology · 2026
10. Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory studyThe International Journal of Neuropsychopharmacology · 2026
11. P1043Unsupervised machine learning to identify distinct CDAI-based response patterns to guselkumab in participants with Crohn’s disease: Post hoc analysis of the pooled GRAVITI and GALAXI 2/3 studiesJournal of Crohn s and Colitis · 2026
12. DOP001Extraintestinal manifestations in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GALAXI 2 & 3 studiesJournal of Crohn s and Colitis · 2026
13. P1110Efficacy of intravenous and subcutaneous guselkumab induction by weight and body mass index in patients with Crohn’s disease: Results from the phase 3 GALAXI and GRAVITI studiesJournal of Crohn s and Colitis · 2026
14. DOP103Intravenous and subcutaneous guselkumab induction are similarly efficacious in patients with ulcerative colitis across weight quartile and BMI subgroups: Week 12 results from the phase 3 QUASAR and ASTRO studiesJournal of Crohn s and Colitis · 2026
15. Improved IOL Power Calculation With Femtosecond Laser Enhanced Refractive Outcome PredictionTranslational Vision Science & Technology · 2025
16. Tandem-Trapped Ion Mobility Spectrometry as a Platform for Conformationally Resolved Analysis of Protein Complexes and BiologicsAnalytical Chemistry · 2025
17. A qualitative burden of disease study in patients with invasive Escherichia coli disease aged ≥ 60 years in the United StatesBMC Infectious Diseases · 2025
18. A randomized study of apalutamide in Chinese patients with non-metastatic castration-resistant prostate canceriScience · 2025
19. Discovery of a non-nucleoside inhibitor that binds to a novel site in the palm domain of the respiratory syncytial virus RNA-dependent RNA polymeraseJournal of Virology · 2025
20. DNA-Encoded Library Screen Identifies Novel Series of Respiratory Syncytial Virus Polymerase InhibitorsJournal of Medicinal Chemistry · 2025